TY - JOUR
T1 - Urinary bladder preservation for muscle-invasive bladder cancer
T2 - A survey among radiation oncologists of Lombardy, Italy
AU - Jereczek-Fossa, Barbara Alicja
AU - Colombo, Renzo
AU - Magnani, Tiziana
AU - Fodor, Cristiana
AU - Alessandra Gerardi, Marianna
AU - Antognoni, Paolo
AU - Barsacchi, Lucia
AU - Bedini, Nice
AU - Bracelli, Stefano
AU - Buffoli, Alberto
AU - Cagna, Emanuela
AU - Catalano, Gianpiero
AU - Gottardo, Stefania
AU - Italia, Corrado
AU - Ivaldi, Giovanni Battista
AU - Masciullo, Stefano
AU - Merlotti, Anna
AU - Sarti, Enrico
AU - Scorsetti, Marta
AU - Serafini, Flavia
AU - Toninelli, Mariasole
AU - Vitali, Elisabetta
AU - Valdagni, Riccardo
AU - Villa, Elisa
AU - Zerini, Dario
AU - De Cobelli, Ottavio
AU - Orecchia, Roberto
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Aims and background: Bladder preservation is a treatment option in muscle-invasive bladder carcinoma. The most investigated approach is a trimodality schedule including maximum transurethral resection of bladder tumor (TURBT) followed by chemoradiotherapy. Our aim was to evaluate the use of bladder preservation by radiation oncologists of the Lombardy region in Italy. Methods and study design: A survey with 13 items regarding data of 2012 was sent to all 32 radiotherapy centers within the collaboration between the Lombardy Oncological Network and the Lombardy Section of the Italian Society of Oncological Radiotherapy. Results: Thirteen centers (41%) answered the survey; the presented data come from 11 active centers. In these centers, 11,748 patients were treated with external-beam radiotherapy in 2012, 100 of whom having bladder cancer (0.9%). 74/100 patients received radiotherapy as palliative treatment for T, N or M lesions. A further 9 and 5 patients received radiotherapy for oligometastatic disease (ablative doses to small volumes) and postoperatively, respectively. Bladder preservation was performed in 12 cases and included trimodality and other strategies (mainly TURBT followed by radiotherapy). A multidisciplinary urology tumor board met regularly in 5 of 11 centers. All responders declared their interest in the Lombardy multicenter collaboration on bladder preservation. Conclusions: Our survey showed that bladder preservation is rarely used in Lombardy despite the availability of the latest radiotherapy technologies and the presence of an urology tumor board in half of the centers. The initiative of multicenter and multidisciplinary collaboration was undertaken to prepare the platform for bladder preservation as a treatment option in selected patients.
AB - Aims and background: Bladder preservation is a treatment option in muscle-invasive bladder carcinoma. The most investigated approach is a trimodality schedule including maximum transurethral resection of bladder tumor (TURBT) followed by chemoradiotherapy. Our aim was to evaluate the use of bladder preservation by radiation oncologists of the Lombardy region in Italy. Methods and study design: A survey with 13 items regarding data of 2012 was sent to all 32 radiotherapy centers within the collaboration between the Lombardy Oncological Network and the Lombardy Section of the Italian Society of Oncological Radiotherapy. Results: Thirteen centers (41%) answered the survey; the presented data come from 11 active centers. In these centers, 11,748 patients were treated with external-beam radiotherapy in 2012, 100 of whom having bladder cancer (0.9%). 74/100 patients received radiotherapy as palliative treatment for T, N or M lesions. A further 9 and 5 patients received radiotherapy for oligometastatic disease (ablative doses to small volumes) and postoperatively, respectively. Bladder preservation was performed in 12 cases and included trimodality and other strategies (mainly TURBT followed by radiotherapy). A multidisciplinary urology tumor board met regularly in 5 of 11 centers. All responders declared their interest in the Lombardy multicenter collaboration on bladder preservation. Conclusions: Our survey showed that bladder preservation is rarely used in Lombardy despite the availability of the latest radiotherapy technologies and the presence of an urology tumor board in half of the centers. The initiative of multicenter and multidisciplinary collaboration was undertaken to prepare the platform for bladder preservation as a treatment option in selected patients.
KW - Bladder preservation
KW - Muscle-invasive bladder cancer
KW - Trimodality approach
UR - http://www.scopus.com/inward/record.url?scp=84930586709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930586709&partnerID=8YFLogxK
U2 - 10.5301/tj.5000235
DO - 10.5301/tj.5000235
M3 - Article
C2 - 25744865
AN - SCOPUS:84930586709
VL - 101
SP - 174
EP - 178
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 2
ER -